The rising demand for GLP-1 medications — widely recognized for their effectiveness in weight management and chronic disease prevention — has created a significant coverage gap in Medicare. Historically, federal law has prohibited Medicare Part D from covering drugs prescribed solely for weight loss. The Medicare GLP-1 Bridge program represents Centers for Medicare & Medicaid Services (CMS)’s first major step toward addressing this gap.
Understanding the CMS GLP-1 Bridge Program for Medicare Beneficiaries
calendar_today
July 21, 2026
person
Brenda Shearer – National Director, EB Select & Medicare
domain
brown-brown